Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.

Khojah AM, Miller ML, Klein-Gitelman MS, Curran ML, Hans V, Pachman LM, Fuleihan RL.

Pediatr Rheumatol Online J. 2019 Aug 28;17(1):61. doi: 10.1186/s12969-019-0365-y.

2.

Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis.

Duvvuri B, Pachman LM, Morgan G, Khojah AM, Klein-Gitelman M, Curran ML, Doty S, Lood C.

Arthritis Rheumatol. 2019 Aug 12. doi: 10.1002/art.41078. [Epub ahead of print]

PMID:
31403247
3.

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovský J, Deakin CT, Dankó K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen PR, Radstake TRDJ, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE; Myositis Genetics Consortium (MYOGEN).

Ann Rheum Dis. 2019 Jul;78(7):996-1002. doi: 10.1136/annrheumdis-2019-215046. Epub 2019 May 28.

4.

Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis.

Throm AA, Alinger JB, Pingel JT, Daugherty AL, Pachman LM, French AR.

JCI Insight. 2018 Nov 15;3(22). pii: 123236. doi: 10.1172/jci.insight.123236.

5.

Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis.

Conklin LS, Merkel PA, Pachman LM, Parikh H, Tawalbeh S, Damsker JM, Cuthbertson DD, Morgan GA, Monach PA, Hathout Y, Nagaraju K, van den Anker J, McAlear CA, Hoffman EP.

Steroids. 2018 Dec;140:159-166. doi: 10.1016/j.steroids.2018.10.008. Epub 2018 Oct 21.

6.

Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Pachman LM, Khojah AM.

J Pediatr. 2018 Apr;195:16-27. doi: 10.1016/j.jpeds.2017.12.053. Review. No abstract available.

7.

Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.

McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW.

Ann Rheum Dis. 2018 Feb;77(2):241-250. doi: 10.1136/annrheumdis-2017-212141. Epub 2017 Oct 30.

8.

Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity.

Briones MR, Morgan GA, Amoruso MC, Rahmani B, Ryan ME, Pachman LM.

RMD Open. 2017 Jul 11;3(1):e000385. doi: 10.1136/rmdopen-2016-000385. eCollection 2017.

9.

Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study.

Xu D, Kacha-Ochana A, Morgan GA, Huang CC, Pachman LM.

Pediatr Rheumatol Online J. 2017 May 17;15(1):42. doi: 10.1186/s12969-017-0171-3.

10.

Environmental factors associated with disease flare in juvenile and adult dermatomyositis.

Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscone-Schreiber LG, Jung LK, Miller FW, Katz JD.

Rheumatology (Oxford). 2017 Aug 1;56(8):1342-1347. doi: 10.1093/rheumatology/kex162.

11.

Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography.

Ibarra M, Rigsby C, Morgan GA, Sammet CL, Huang CC, Xu D, Targoff IN, Pachman LM.

Pediatr Rheumatol Online J. 2016 Nov 29;14(1):64.

12.

MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis.

Xu D, Huang CC, Kachaochana A, Morgan GA, Bonaldo MF, Soares MB, Costa F, Sarwark J, Sredni ST, Pachman LM.

J Rheumatol. 2016 Jan;43(1):161-8. doi: 10.3899/jrheum.141474. Epub 2015 Dec 1.

PMID:
26628598
13.

Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.

Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Rider LG, Cobb J, Platt H, Molberg Ø, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA; Myositis Genetics Consortium.

Ann Rheum Dis. 2016 Aug;75(8):1558-66. doi: 10.1136/annrheumdis-2015-208119. Epub 2015 Sep 11.

14.

Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.

Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI; Myositis Genetics Consortium.

Genes Immun. 2015 Oct;16(7):470-80. doi: 10.1038/gene.2015.28. Epub 2015 Aug 20.

15.

A mouse model of human primitive neuroectodermal tumors resulting from microenvironmentally-driven malignant transformation of orthotopically transplanted radial glial cells.

Malchenko S, Sredni ST, Hashimoto H, Kasai A, Nagayasu K, Xie J, Margaryan NV, Seiriki K, Lulla RR, Seftor RE, Pachman LM, Meltzer HY, Hendrix MJ, Soares MB.

PLoS One. 2015 Mar 31;10(3):e0121707. doi: 10.1371/journal.pone.0121707. eCollection 2015.

16.

Pilot study of etanercept in patients with refractory juvenile dermatomyositis.

Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM.

Arthritis Care Res (Hoboken). 2014 May;66(5):783-7.

17.

Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders.

Miller FW, Cooper RG, Vencovský J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, O'Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI, Gregersen PK; Myositis Genetics Consortium.

Arthritis Rheum. 2013 Dec;65(12):3239-47. doi: 10.1002/art.38137.

18.

Interferon-α induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis.

Balboni I, Niewold TB, Morgan G, Limb C, Eloranta ML, Rönnblom L, Utz PJ, Pachman LM.

Arthritis Rheum. 2013 Sep;65(9):2424-9. doi: 10.1002/art.38038.

19.

Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis.

Quiñones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1697-701. doi: 10.1002/acr.22041.

20.

Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters in children.

Prestridge A, Morgan G, Ferguson L, Huang CC, Pachman LM.

Arthritis Care Res (Hoboken). 2013 Sep;65(9):1424-31. doi: 10.1002/acr.22014.

21.
22.

Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsy samples from patients with untreated juvenile dermatomyositis suggest self-renewal capacity.

Wang M, Xie H, Shrestha S, Sredni S, Morgan GA, Pachman LM.

Arthritis Rheum. 2012 Oct;64(10):3478-85. doi: 10.1002/art.34573.

23.

Ovarian teratoma mimicking features of juvenile dermatomyositis in a child.

Ibarra M, Chou P, Pachman LM.

Pediatrics. 2011 Nov;128(5):e1293-6. doi: 10.1542/peds.2010-2115. Epub 2011 Oct 3.

24.

Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis.

Eimer MJ, Brickman WJ, Seshadri R, Ramsey-Goldman R, McPherson DD, Smulevitz B, Stone NJ, Pachman LM.

J Pediatr. 2011 Nov;159(5):795-801. doi: 10.1016/j.jpeds.2011.05.015. Epub 2011 Jul 23.

25.

Familial aggregation of autoimmune disease in juvenile dermatomyositis.

Niewold TB, Wu SC, Smith M, Morgan GA, Pachman LM.

Pediatrics. 2011 May;127(5):e1239-46. doi: 10.1542/peds.2010-3022. Epub 2011 Apr 18.

26.

Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis.

Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM.

Arch Dermatol. 2011 Jul;147(7):831-5. doi: 10.1001/archdermatol.2011.49. Epub 2011 Mar 21.

PMID:
21422326
27.

Autoantibody to PL-12 (Anti-Alanyl-tRNA synthetase) in an African American girl with juvenile dermatomyositis and resolution of interstitial lung disease.

Vega P, Ibarra M, Prestridge A, Pachman LM.

J Rheumatol. 2011 Feb;38(2):394-5. doi: 10.3899/jrheum.100608. No abstract available.

PMID:
21285181
28.

Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome.

Ibarra MF, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan G, Pachman LM, O'Gorman MR.

Clin Vaccine Immunol. 2011 Apr;18(4):609-14. doi: 10.1128/CVI.00306-10. Epub 2011 Jan 26.

29.

Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis.

Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM.

J Pediatr. 2010 Oct;157(4):653-7. doi: 10.1016/j.jpeds.2010.04.034.

30.

The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.

Ruperto N, Pistorio A, Ravelli A, Rider LG, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Gare BA, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Arthritis Care Res (Hoboken). 2010 Nov;62(11):1533-41. doi: 10.1002/acr.20280. Epub 2010 Jun 25.

31.

Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis.

Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM.

Arthritis Care Res (Hoboken). 2010 Oct;62(10):1446-51. doi: 10.1002/acr.20269.

32.

Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman LM.

Arthritis Rheum. 2010 Sep;62(9):2813-22. doi: 10.1002/art.27529.

33.

Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies.

Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE.

Arthritis Care Res (Hoboken). 2010 Apr;62(4):465-72. doi: 10.1002/acr.20035.

34.

Calcification in a case of circumscribed myositis ossificans.

Ibarra M, Chou PM, Pachman LM, Zhao YD, Boskey AL.

J Rheumatol. 2010 Apr;37(4):876. doi: 10.3899/jrheum.090833. No abstract available.

35.

Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis.

Ostrowski RA, Sullivan CL, Seshadri R, Morgan GA, Pachman LM.

Arthritis Rheum. 2010 May;62(5):1533-8. doi: 10.1002/art.27379.

36.

Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.

Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM.

Arthritis Care Res (Hoboken). 2010 Feb;62(2):219-25. doi: 10.1002/acr.20071.

37.

Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW; IMACS Group.

Arthritis Rheum. 2009 Nov;60(11):3425-35. doi: 10.1002/art.24904.

38.

Characterization of dystrophic calcification induced in mice by cardiotoxin.

Zhao Y, Urganus AL, Spevak L, Shrestha S, Doty SB, Boskey AL, Pachman LM.

Calcif Tissue Int. 2009 Sep;85(3):267-75. doi: 10.1007/s00223-009-9271-5. Epub 2009 Aug 20.

39.

Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM.

Arthritis Rheum. 2009 Jun;60(6):1815-24. doi: 10.1002/art.24555.

40.

Juvenile dermatomyositis calcifications selectively displayed markers of bone formation.

Urganus AL, Zhao YD, Pachman LM.

Arthritis Rheum. 2009 Apr 15;61(4):501-8. doi: 10.1002/art.24391.

41.

Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis.

Chen YW, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM.

BMC Immunol. 2008 Jul 31;9:43. doi: 10.1186/1471-2172-9-43.

42.

Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.

Feldman BM, Rider LG, Reed AM, Pachman LM.

Lancet. 2008 Jun 28;371(9631):2201-12. doi: 10.1016/S0140-6736(08)60955-1. Review.

PMID:
18586175
43.

The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis.

Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM.

Arthritis Rheum. 2008 Jul 15;59(7):989-95. doi: 10.1002/art.23829.

44.

Autoantibody to signal recognition particle in African American girls with juvenile polymyositis.

Rouster-Stevens KA, Pachman LM.

J Rheumatol. 2008 May;35(5):927-9. Epub 2008 Mar 1.

PMID:
18322984
45.

Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM.

Arthritis Rheum. 2008 Feb;58(2):571-6. doi: 10.1002/art.23299.

46.

Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM.

Arthritis Rheum. 2008 Feb 15;59(2):222-6. doi: 10.1002/art.23341.

47.

Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease.

Zhao Y, Fedczyna TO, McVicker V, Caliendo J, Li H, Pachman LM.

Clin Immunol. 2007 Nov;125(2):165-72. Epub 2007 Aug 20.

48.

RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.

Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, Pachman LM.

Arthritis Rheum. 2007 Mar;56(3):977-83.

49.

Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation.

Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, Giczewski D, Webb C, Spevak L, Boskey AL.

Arthritis Rheum. 2006 Oct;54(10):3345-50.

50.

Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis.

Pachman LM, Boskey AL.

Curr Rheumatol Rep. 2006 Jun;8(3):236-43. Review.

PMID:
16901083

Supplemental Content

Loading ...
Support Center